Vitiligo induced by immune checkpoint inhibitors in melanoma patients: an expert opinion

Introduction: Treatment with immune checkpoint inhibitors in melanoma patients can cause immune-related adverse effects, such as vitiligo. In vitiligo, specific autoimmunity against melanocytes results depigmentation of the skin. Melanoma-associated vitiligo occurring treated be seen a good prognostic sign higher survival rates melanoma-associated cases have been reported.Areas covered: This review gives an insight into pathophysiology, clinical presentation, and management caused by inhibitors.Expert opinion: Development induced could marker for response overall survival. Induction these also potentially lead to better rates. Further research should focus on several aspects screening registration, more understanding pathophysiology type predictive value inhibitors.